tetano
Editor, Senior Moderator
Front Immunol
. 2022 Jan 12;12:809937.
doi: 10.3389/fimmu.2021.809937. eCollection 2021.
Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment
André F Rendeiro[SUP] 1 2 [/SUP], Charles Kyriakos Vorkas[SUP] 3 [/SUP], Jan Krumsiek[SUP] 1 2 [/SUP], Harjot K Singh[SUP] 3 [/SUP], Shashi N Kapadia[SUP] 3 [/SUP], Luca Vincenzo Cappelli[SUP] 4 [/SUP], Maria Teresa Cacciapuoti[SUP] 4 [/SUP], Giorgio Inghirami[SUP] 4 [/SUP], Olivier Elemento[SUP] 1 2 [/SUP], Mirella Salvatore[SUP] 3 5 [/SUP]
Affiliations
Abstract
Deep understanding of the SARS-CoV-2 effects on host molecular pathways is paramount for the discovery of early biomarkers of outcome of coronavirus disease 2019 (COVID-19) and the identification of novel therapeutic targets. In that light, we generated metabolomic data from COVID-19 patient blood using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. We find considerable changes in serum metabolome composition of COVID-19 patients associated with disease severity, and response to tocilizumab treatment. We built a clinically annotated, biologically-interpretable space for precise time-resolved disease monitoring and characterize the temporal dynamics of metabolomic change along the clinical course of COVID-19 patients and in response to therapy. Finally, we leverage joint immuno-metabolic measurements to provide a novel approach for patient stratification and early prediction of severe disease. Our results show that high-dimensional metabolomic and joint immune-metabolic readouts provide rich information content for elucidation of the host's response to infection and empower discovery of novel metabolic-driven therapies, as well as precise and efficient clinical action.
Keywords: COVID-19; immunology; infection biology; metabolism; precision medicine.
. 2022 Jan 12;12:809937.
doi: 10.3389/fimmu.2021.809937. eCollection 2021.
Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment
André F Rendeiro[SUP] 1 2 [/SUP], Charles Kyriakos Vorkas[SUP] 3 [/SUP], Jan Krumsiek[SUP] 1 2 [/SUP], Harjot K Singh[SUP] 3 [/SUP], Shashi N Kapadia[SUP] 3 [/SUP], Luca Vincenzo Cappelli[SUP] 4 [/SUP], Maria Teresa Cacciapuoti[SUP] 4 [/SUP], Giorgio Inghirami[SUP] 4 [/SUP], Olivier Elemento[SUP] 1 2 [/SUP], Mirella Salvatore[SUP] 3 5 [/SUP]
Affiliations
- PMID: 35095900
- PMCID: PMC8790058
- DOI: 10.3389/fimmu.2021.809937
Abstract
Deep understanding of the SARS-CoV-2 effects on host molecular pathways is paramount for the discovery of early biomarkers of outcome of coronavirus disease 2019 (COVID-19) and the identification of novel therapeutic targets. In that light, we generated metabolomic data from COVID-19 patient blood using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. We find considerable changes in serum metabolome composition of COVID-19 patients associated with disease severity, and response to tocilizumab treatment. We built a clinically annotated, biologically-interpretable space for precise time-resolved disease monitoring and characterize the temporal dynamics of metabolomic change along the clinical course of COVID-19 patients and in response to therapy. Finally, we leverage joint immuno-metabolic measurements to provide a novel approach for patient stratification and early prediction of severe disease. Our results show that high-dimensional metabolomic and joint immune-metabolic readouts provide rich information content for elucidation of the host's response to infection and empower discovery of novel metabolic-driven therapies, as well as precise and efficient clinical action.
Keywords: COVID-19; immunology; infection biology; metabolism; precision medicine.